Phase I-II, Randomized, Intraindividually Placebo Controlled Clinical Trial, to Evaluate the Efficacy of Autologous Melanocyte Transplantion on Amniotic Membrane as a Substrate for Patients With Stable Vitiligo.

Fecha de inicio: 1 de diciembre de 2010

Inclusion criteria Patients must voluntarily provide informed consent before any of the tests included in the trial which do not form part of standard treatment can be performed. Mentally stable patients, suffering from piebaldism, vitiligo of metameric distribution, focal or generalized vitiligo which has remained stable for at least one year without de-pigmentation or spontaneous re-pigmentation after standard medical treatment. A minimum hypopigmented area to treat of 100 cm2 (at least 30 cm2 for each of the therapeutic options). For women of child-bearing age, a negative pregnancy test. Exclusion criteria: Women who are pregnant or breast-feeding. Positive results in any of the blood tests given Concomitant serious illness. Patients who have received any agent currently the focus of research in the 30 days prior to their inclusion. Patients currently participating in another clinical trial or receiving any other agent currently the focus of research.